← Back to Search

Behavioural Intervention

Embodied Conversational Agent for Cancer (ECA-PRO Aim 3 Trial)

N/A

Waitlist Available

Led By Michael Paasche-Orlow, MD, MPH

Research Sponsored by Tufts Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 weeks

Awards & highlights

ECA-PRO Aim 3 Trial Summary

This trial tests a computer character that talks to you like a person, to improve health communication & engagement for people with limited health literacy.

Who is the study for?

This trial is for English or Spanish-speaking adults with cancer who can consent independently, have good hearing and vision (with correction), and are patients of oncologists at Boston Medical Center. There are no specific exclusion criteria.Check my eligibility

What is being tested?

The study tests an Embodied Conversational Agent (ECA) tool designed to improve patient-reported outcomes in cancer care by simulating face-to-face conversation. It also uses REDCap surveys to collect data on its effectiveness.See study design

What are the potential side effects?

Since the interventions involve non-medical tools like a conversational agent and surveys, there aren't typical medical side effects. However, participants may experience discomfort or fatigue from prolonged interaction with technology.

ECA-PRO Aim 3 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The degree of missing data will be investigated to gauge the extent to which patients are actively engaging with the ECA-PRO system.

Secondary outcome measures

Ability to participate in social roles and activities

Anxiety

Depression

+4 more

ECA-PRO Aim 3 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Embodied Conversational AgentExperimental Treatment1 Intervention

The ECA systems compromises 1) a smartphone based ECA patient interface; 2) clinician authoring tool, to enable new measurement systems to be rapidly configured 3) clinician and patient data visualizations; and 4) a central server with relation database, administrative user interfaces and ability to send asynchronous notifications to users' smartphones.

Group II: RedCap SurveyActive Control1 Intervention

An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Embodied Conversational Agent

2018

N/A

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Tufts Medical CenterLead Sponsor

255 Previous Clinical Trials

255,168 Total Patients Enrolled

Boston Medical CenterOTHER

383 Previous Clinical Trials

871,049 Total Patients Enrolled

Michael Paasche-Orlow, MD, MPHPrincipal InvestigatorTufts Medical Center

7 Previous Clinical Trials

13,875 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has enrollment for this trial commenced?

"According to clinicaltrials.gov, the initial posting for this trial was on April 1st of 2022 and its last update occured on July 6th 2023; thus, it is no longer actively recruiting candidates. Nevertheless, there are 543 other studies that may be looking for enrollees at present."

Answered by AI

What results is this investigation attempting to obtain?

"This 6-week medical trial is designed to assess the efficacy of ECA-PRO as a tool for medication adherence in breast cancer patients. Secondary objectives include measuring fatigue, depression and anxiety levels through four items from PROMIS profile that participants will rate on a scale of 1-5 (1 representing never, 5 always). The data collection process will be done either with an ECA or REDCap system depending on the type of intervention received by each patient."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Improving PRO for Patients With Cancer Using ECAs and Data Visualization

2024. "Improving PRO for Patients With Cancer Using ECAs and Data Visualization". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05948618.